about
Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature.Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.Strategies to design clinical studies to identify predictive biomarkers in cancer research.Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.Biosimilar biologic drugs: a new frontier in medical care.Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups.Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaCharacterizing the outcomes of metastatic papillary renal cell carcinoma.Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate.Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment.Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.Assessing the Contemporary Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Another Step in the Right DirectionAutoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor TreatmentRisk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal CellRadiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell CarcinomaThree case reports: Temporal association between tyrosine-kinase inhibitor-induced hepatitis and immune checkpoint inhibitors in renal cell carcinomaOutcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint InhibitorsPrognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell CarcinomaClinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell CarcinomaSEOM clinical guideline for treatment of kidney cancer (2019)Optimising first-line treatment for metastatic renal cell carcinoma
P50
Q31109447-D6CBF559-D207-4BD1-A0F0-24211F898934Q34438928-D449C78C-720D-45C8-A09C-0C8B0100C44FQ36693159-4B8E8F5B-A474-46DA-B958-286AA09E84A3Q38014621-EB672713-794F-48E6-903D-71BCD849B705Q38530784-33A74F27-D9B2-4E9A-8E5E-BB9AB2F2F4E9Q38611436-8C98D832-E1FC-4A38-9E84-A5BE29E8D695Q38752269-B8E67516-445B-47B4-AAA4-DA9EECCC11E8Q38755164-9E41E990-1729-4E91-83DB-24D235D34E36Q38770451-70D23121-6030-4E84-85EE-7998BC311BA9Q38836367-3369D16A-A5A0-4289-9630-7D958B6FA626Q38865046-ED0F870E-3163-4BD2-936D-3D8B3E78B7C1Q39200937-99621CDD-2735-4330-9E4A-E6E78D803387Q39476764-A536D6A9-F1CA-4089-8FF5-75F1173EA4E9Q39608223-208E9C24-17A7-434B-9281-13ED4B9DF4DFQ41006964-384EDCFC-E55E-4646-80FE-F1C4BFF5FA1FQ41975337-D7A71284-F557-4976-8207-C43EEA183406Q42172414-9A9404A5-845B-4752-A298-18A31FF52BAEQ42420987-0EF55320-A5FE-4799-AA1A-086449FCF1F6Q42812053-25A349F9-88A2-4020-B534-7EFC4FCEDCFAQ47580959-E5AD6AB4-9453-4967-A3AE-4AC28B033A5DQ48689595-AE6F44A2-C85E-44B5-B28F-AB2B5C286F40Q85336011-45C1CD8D-2BB6-44E6-B88A-8D90DD3A9C85Q86018157-AF7014A7-AA72-4539-BA78-877DB96DB515Q86632070-7C2E92AC-B021-440D-8449-EFD960E000A8Q86754201-39C448F7-F170-4A6F-A2EB-16FD82059905Q91437085-02DC4C8E-5DF5-453D-A24A-455BAA7EA193Q91570820-C0627BAD-3C8A-4725-8129-EB519948E27DQ92154621-A232F709-C539-4787-934A-7A3487260738Q92573718-A11F5A36-C82B-44B8-9B06-4F04E36067BCQ93020159-F21C3EC6-0B7A-432A-AD0C-B488A211EB5BQ95592085-9B8D19D0-99A4-4B40-9844-58356DCA87E8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Guillermo de Velasco
@ast
Guillermo de Velasco
@en
Guillermo de Velasco
@es
Guillermo de Velasco
@nl
type
label
Guillermo de Velasco
@ast
Guillermo de Velasco
@en
Guillermo de Velasco
@es
Guillermo de Velasco
@nl
prefLabel
Guillermo de Velasco
@ast
Guillermo de Velasco
@en
Guillermo de Velasco
@es
Guillermo de Velasco
@nl
P106
P21
P31
P496
0000-0002-8075-0666